DVA DaVita
Permanent stock page ↗Health Care · S&P 500
Next earnings: not announced yet
What 10 analyst firms say about DaVita: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
7 rated views · 10 analyst/firm records · 10 firms
Radar score
- S&P 500 · Top Picks · 6MBelow the Radar threshold of 8029
- S&P 500 · Safest consensus · 6MBelow the Radar threshold of 8020
Recent analyst activity · last 90 days
Our tracked history has 4 reports on DVA from 4 analyst firms in the last 90 days (10 firms in the past year).
Comparing each firm's latest target with its previous one: 1 raised its price target and 1 lowered it.
No firm's latest available rating differs from its previous one.
Latest observed target change: UBS raised its target from $270.00 (set 10 Jul 2026) to $287.00 on 2 Nov 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Barclays | Andrew Mok | Hold | 30 Oct 2026 | 216.00 USD |
| Deutsche Bank | Pito Chickering | Buy | 5 Aug 2026 | 265.00 USD |
| Oppenheimer | Unnamed analyst | — | 7 Aug 2026 | 220.00 USD |
| Raymond James | Unnamed analyst | — | 7 Aug 2026 | 220.00 USD |
| TD Cowen | Ryan Langston | Buy | 21 Oct 2026 | Conflicting reports · excluded |
| Truist | David MacDonald | Hold | 7 Aug 2026 | 215.00 USD |
| UBS | Aj Rice | Buy | 2 Nov 2026 | 287.00 USD |
| Weiss Ratings | Unnamed analyst | — | 9 Oct 2026 | — |
| Wolfe Research | Justin Lake | Hold | 28 Feb 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 6 Jul 2026 | 190.00 USD |
Partial coverage · checked 6 Nov (6 Nov 2026, 02:21 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.